BALAXI PHARMA LTD vs CIPLA LTD
A side-by-side comparison of BALAXI PHARMA LTD (BALAXI) and CIPLA LTD (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads BALAXI vs CIPLA on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability04
- Growth02
- Size & financial health04
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CIPLA takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
CIPLA takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Stock is trading at 0.50 times its book value"]
- − ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of 3.15% over past five years.", "Company has a low return on equity of -3.58% over last 3 years.", "Company might be capitalizing the interest cost", "Earnings include an other income of Rs.3.62 Cr.", "Company has high debtors of 184 days.", "Promoter holding has decreased over last 3 years: -5.23%"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.